Growth hormone & endocrine research
Erythropoietin (EPO) (EPO): Research Overview
Hormone that drives red blood cell production. Approved for anaemia; banned in competitive sport.
Also known as erythropoietin · epoetin · EPO
What is Erythropoietin?
Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients.
What is Erythropoietin researched for?
- Primary FDA-approved indication for anemia secondary to chronic kidney disease.
- FDA-approved for treating anemia in cancer patients receiving chemotherapy.
- Used to reduce need for blood transfusions in certain surgical settings.
- Increases oxygen delivery to muscles, improving endurance capacity. Banned by WADA.
- May accelerate adaptation to high altitude by increasing red blood cell mass.
How does Erythropoietin work?
EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production.
Reported targets: EPOR, erythropoietin receptor
References
Erythropoietin regulation of red blood cell production PMC/NCBI
2020
Comprehensive review of EPO's oxygen-sensing mechanism and regulation of RBC production.
Review or meta-analysis
Erythropoietin Stimulating Agents StatPearls
2024
FDA-approved indications include CKD anemia and chemotherapy-induced anemia. Risks increase when hemoglobin exceeds 11-12 g/dL.
Erythropoiesis-stimulating agents and other methods to enhance oxygen transport PMC
2008
rHuEPO increases O2 supply to muscles and boosts performance in endurance sports.
The mechanism of erythropoietin action PubMed
1992
EPO promotes survival of erythroid progenitors by protecting from apoptosis.
Common questions
Why is EPO banned in sports if it's FDA-approved as medicine?
EPO is FDA-approved specifically for anemia in kidney disease and chemotherapy patients—narrow medical indications. It's banned in sports because it boosts oxygen delivery far beyond medical therapeutic levels, providing unfair endurance advantages. The performance-enhancing effects at doses used by athletes vastly exceed what's used medically.
At what hemoglobin level does EPO become dangerous?
Medical guidelines recommend keeping hemoglobin below 11-12 g/dL during EPO therapy because higher levels significantly increase cardiovascular risks including blood clots, stroke, and heart attack. This ceiling exists because excessive oxygen-carrying capacity paradoxically becomes harmful, increasing blood viscosity dangerously.